Medincell proposes Dr. Elisabeth Svanberg for board seat

Medincell (Euronext Paris: MEDCL) announced that its board of directors will propose the appointment of Dr. Elisabeth Svanberg as an independent director at the company's Annual General Meeting on September 30, 2026.

If elected by shareholders, Dr. Svanberg would be expected to serve as chair of Medincell's Remuneration & Nomination Committee. Her election would mean that 50% of Medincell's board will have been renewed since 2025, following the earlier appointments of Dr. Pascal Touchon, Dr. Sharon Mates, and Dr. Charles Kunsch.

Dr. Svanberg holds an MD and PhD and is a board-certified surgeon and Associate Professor. She has held senior global leadership positions at Janssen Pharmaceutical, Bristol-Myers Squibb, and Serono/Merck-Serono. She currently serves as Partner at Ventac Partners and holds non-executive board roles including Chair of EPICS Therapeutics and board member of LEO Pharma A/S. She has also served on the boards of Galapagos NV, Egetis Therapeutics AB, and Swedish Orphan Biovitrum AB, among others.

Separately, shareholders at the meeting will be asked to approve a process for the future appointment of an employee shareholder representative to the board, expected to take effect in 2027.

The board also noted the departures of Virginie Lleu and Dr. Sabri Markabi, both of whom will step down at the close of the Annual General Meeting. Dr. Markabi served as Vice-Chairman of the board from 2018 to 2025 and has served as a board observer over the past year.

You May Also Be Interested In

• Trump: nominate Heidi Overton, MD, PhD, as our next FDA commissioner
• Abercrombie & Fitch adds Lovesac president to its board
• J & J Snack Foods names Roy C. Jackson as lead independent director